Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement

The overall negative assessment of the commonly used EPR policy suggests a possible need for change in current pricing practice. However, positions about alternative pricing options differ considerably across stakeholders. It is recommended to further explore the motivation of the stakeholders for their assessments in a qualitative research project.